Cargando…

Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization

IMPORTANCE: Prior studies have observed an association between the burden of atherosclerotic vascular disease and the risk of venous thromboembolism (VTE). The association is not well described in peripheral artery disease (PAD) after lower extremity revascularization (LER). OBJECTIVE: To describe t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hess, Connie N., Szarek, Michael, Anand, Sonia S., Bauersachs, Rupert M., Patel, Manesh R., Debus, E. Sebastian, Nehler, Mark R., Capell, Warren H., Beckman, Joshua A., Piazza, Gregory, Henkin, Stanislav, Bura-Rivière, Alessandra, Lawall, Holger, Roztocil, Karel, Hsia, Judith, Muehlhofer, Eva, Berkowitz, Scott D., Haskell, Lloyd P., Bonaca, Marc P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218845/ https://www.ncbi.nlm.nih.gov/pubmed/35731517 http://dx.doi.org/10.1001/jamanetworkopen.2022.15580

Ejemplares similares

Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD
por: Hess, Connie N., et al.
Publicado: (2022)

Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD
por: Bonaca, Marc P., et al.
Publicado: (2022)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Rivaroxaban and the EINSTEIN clinical trial programme
por: Cohen, Alexander T., et al.
Publicado: (2019)

Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease
por: Biswas, Minakshi P., et al.
Publicado: (2021)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

IMPACT OF THROMBOPROPHYLACTIC STRATEGY ON BLEEDING RISK AMONG IN- AND OUTPATIENTS WITH COVID-19
por: Svet, Mark, et al.
Publicado: (2021)

Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis
por: Bauersachs, Rupert, et al.
Publicado: (2021)

Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial
por: Hess, Connie N., et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020)

Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial
por: Piazza, Gregory, et al.
Publicado: (2023)

Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial
por: Hess, Connie N., et al.
Publicado: (2023)

Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease
por: Szarek, Michael, et al.
Publicado: (2022)

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease
por: Dagenais, Gilles R, et al.
Publicado: (2021)

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies
por: Prins, Martin H, et al.
Publicado: (2013)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England
por: Portas, Laura, et al.
Publicado: (2022)

Updated Renal Dosage Recommendations for Rivaroxaban in Patients Experiencing or at Risk of Thromboembolic Disease
por: Volkl, Albert A., et al.
Publicado: (2023)

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban
por: Breithardt, Günter, et al.
Publicado: (2016)

Is Paclitaxel Causing Mortality During Lower‐Extremity Revascularization?
por: Swaminathan, Rajesh V., et al.
Publicado: (2019)

A Cross‐Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies
por: Zhang, Liping, et al.
Publicado: (2017)

Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions
por: Canonico, Mario Enrico, et al.
Publicado: (2023)

Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation
por: Zhang, Liping, et al.
Publicado: (2020)

Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization
por: Yu, Qingyuan, et al.
Publicado: (2022)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
por: Leef, George C., et al.
Publicado: (2017)

Revascularization Outcomes of Acute Limb Ischemia in Patients With COVID-19
por: Kabeil, Mahmood, et al.
Publicado: (2022)

Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and nonvalvular atrial fibrillation
por: Patel, Manesh R., et al.
Publicado: (2018)

Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial
por: Piccini, Jonathan P., et al.
Publicado: (2014)

Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
por: Cohen, Alexander Thomas, et al.
Publicado: (2011)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Rivaroxaban and Hemostasis in Emergency Care
por: Koscielny, Jürgen, et al.
Publicado: (2014)

Rivaroxaban for the Treatment of Pulmonary Embolism
por: Vanassche, Thomas, et al.
Publicado: (2013)

Rivaroxaban: Haemoptysis: case report
Publicado: (2020)

Efficacy of rivaroxaban for pulmonary embolism
por: Jia, Juan, et al.
Publicado: (2019)

The role of rivaroxaban in eosinophilic myocarditis
por: Bodagh, Carla, et al.
Publicado: (2022)

Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis
por: Lipardi, Concetta, et al.
Publicado: (2021)

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
por: Moore, Kenneth T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_snsbj7mh7pvt996aa2s9hqfia3